Recent Updates
Recently added Catalysts
SRPT Negative Sentiment Score: 25/100

Sarepta Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Sarepta Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 – SRPT

Key Takeaway: Sarepta Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its ELEVIDYS gene therapy for Duchenne muscular dystrophy. The complaint claims that the therapy posed significant safety risks and that trial protocols failed to detect severe side effects. As a result, the company may have to halt recruitment and dosing in trials, potentially attracting regulatory scrutiny. Shareholders are encouraged to participate in the lawsuit, which has a lead plaintiff deadline of August 25, 2025.

Market Sentiment Analysis

CONCERNS & RISKS

  • ELEVIDYS gene therapy poses significant safety risks to patients.
  • Trial protocols failed to detect severe side effects.
  • Adverse events could cause recruitment and dosing halts.
  • The company faces increased regulatory scrutiny due to safety issues.

Full Press Release Details

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT).
Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: June 22, 2023 to June 24, 2025
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy’s present and expanded approvals; and (iv) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements.
DEADLINE: August 25, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/sarepta-loss-submission-form/?id=156709&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SRPT during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is August 25, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Phone: (646) 453-8903

Tags

Frequently Asked Questions

What is the class period for Sarepta Therapeutics shareholders?

The class period for Sarepta Therapeutics shareholders is from June 22, 2023, to June 24, 2025.

What should shareholders do if they purchased SRPT shares?

Shareholders who bought SRPT shares are encouraged to register for potential lead plaintiff appointment.

What allegations are made against Sarepta Therapeutics?

The allegations include misleading statements regarding the safety and trial processes of ELEVIDYS.

What is the deadline to register for the class action?

The deadline to register for the class action is August 25, 2025.

Is there a cost to participate in the class action?

There is no cost or obligation for shareholders to participate in the class action.

Last updated: Jul 16, 2025